Beautiful Virgin Islands

Tuesday, Jun 03, 2025

From COVID to Cancer: Pfizer's Shopping Spree Continues with $43 Billion Seagen Acquisition

Pfizer is looking beyond the COVID-19 pandemic and making some major moves in the world of cancer treatments. The pharmaceutical giant has just announced a $43 billion deal to acquire Seagen, a leading innovator in targeted cancer therapies.
This latest acquisition by Pfizer will add four approved cancer therapies to their portfolio, which together generated nearly $2 billion in sales in 2022. Seagen is a pioneer in antibody-drug conjugates, which essentially work like "guided missiles" designed to target and destroy cancer cells while leaving healthy cells unharmed.

CEO Albert Bourla says that this deal will help Pfizer move into an area that is more protected from regulatory and patent issues. It's also a smart move for Seagen, as the Biden administration's Inflation Reduction Act is set to benefit the company's expensive treatments, which will be more accessible to patients with out-of-pocket healthcare spending caps.

Pfizer will pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price, which sent Seagen's shares soaring to $200 in early trading.

This acquisition comes as Pfizer is preparing for a significant decline in COVID-19 product sales and stiff competition for some of its top-selling drugs. The company expects to generate more than $10 billion in sales from Seagen products alone by 2030, in addition to the $15 billion from its other recent acquisitions.

Pfizer's recent deals include the purchase of Global Blood Therapeutics for $5.4 billion, migraine drug maker Biohaven Pharmaceutical Holding for $11.6 billion, and drug developer Arena Pharmaceuticals for $6.7 billion.

Pfizer's current portfolio of oncology therapies includes 24 approved drugs, while Seagen's includes Adcetris for lymphoma, Padcev for bladder cancers, Tivdak for cervical cancer, and breast cancer treatment Tukysa.

The deal is expected to be completed in late 2023 or early 2024, and while antitrust regulators may closely review it due to its size, Pfizer believes it will eventually be approved.

This is definitely one to watch as Pfizer makes bold moves in the world of cancer treatments and continues to diversify its portfolio beyond COVID-19 products.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
China Accuses US of Violating Trade Truce
Panama Port Owner Balances US-China Pressures
France Implements Nationwide Outdoor Smoking Ban to Protect Children
German Chancellor Merz Keeps Putin Guessing on Missile Strategy
Mandelson Criticizes UK's 'Fetish' for Abandoning EU Regulations
British Fishing Boat Owner Fined €30,000 by French Authorities
Dutch government falls as far-right leader Wilders quits coalition
Harvard Urges US to Unfreeze Funds for Public Health Research
Businessman Mauled by Lion at Luxury Namibian Lodge
Researchers Consider New Destinations Beyond the U.S.
53-Year-Old Doctor Claims Biological Age of 23
Trump Struggles to Secure Trade Deals With China and Europe
Russia to Return 6,000 Corpses Under Ukraine Prisoner Swap Deal
Microsoft Lays Off Hundreds More Amid Restructuring
Harvey Weinstein’s Publicist Embraces Notoriety
Macron and Meloni Seek Unity Despite Tensions
Trump Administration Accused of Obstructing Deportation Cases
Newark Mayor Sues Over Arrest at Immigration Facility
Center-Left Candidate Projected to Win South Korean Presidency
Trump’s Tariffs Predicted to Stall Global Economic Growth
South Korea’s President-Elect Expected to Take Softer Line on Trump and North Korea
Trump’s China Strategy Remains a Geopolitical Puzzle
Ukraine Executes Long-Range Drone Strikes on Russian Airbases
Conservative Karol Nawrocki wins Poland’s presidential election
Study Identifies Potential Radicalization Risk Among Over One Million Muslims in Germany
Good news: Annalena Baerbock Elected President of the UN General Assembly
Apple Appeals EU Law Over User Data Sharing Requirements
South Africa: "First Black Bank" Collapses after Being Looted by Owners
Poland will now withdraw from the EU migration pact after pro-Trump nationalist wins Election
"That's Disgusting, Don’t Say It Again": The Trump Joke That Made the President Boil
Trump Cancels NASA Nominee Over Democratic Donations
Paris Saint-Germain's Greatest Triumph Is Football’s Lowest Point
OnlyFans for Sale: From Lockdown Lifeline to Eight-Billion-Dollar Empire
Mayor’s Security Officer Implicated | Shocking New Details Emerge in NYC Kidnapping Case
Hegseth Warns of Potential Chinese Military Action Against Taiwan
OPEC+ Agrees to Increase Oil Output for Third Consecutive Month
Jamie Dimon Warns U.S. Bond Market Faces Pressure from Rising Debt
Turkey Detains Istanbul Officials Amid Anti-Corruption Crackdown
Taylor Swift Gains Ownership of Her First Six Albums
Bangkok Ranked World's Top City for Remote Work in 2025
Satirical Sketch Sparks Political Spouse Feud in South Korea
Indonesia Quarry Collapse Leaves Multiple Dead and Missing
South Korean Election Video Pulled Amid Misogyny Outcry
Asian Economies Shift Away from US Dollar Amid Trade Tensions
Netflix Investigates Allegations of On-Set Mistreatment in K-Drama Production
US Defence Chief Reaffirms Strong Ties with Singapore Amid Regional Tensions
Vietnam Faces Strategic Dilemma Over China's Mekong River Projects
Malaysia's First AI Preacher Sparks Debate on Islamic Principles
White House Press Secretary Criticizes Harvard Funding, Advocates for Vocational Training
France to Implement Nationwide Smoking Ban in Outdoor Spaces Frequented by Children
×